source
- Hims sales dip as telehealth rivals intensify; Bristol partners with Chinese firm, other biotech updatesHims reported lower sales this quarter, attributing the shortfall to growing competition from other telehealth providers. Bristol announced a new partnership with Chinese drugmaker Hengrui Pharma…
- Pfizer, Arvinas sell recently approved breast cancer drug to Rigel for $35 millionPfizer and its partner Arvinas have agreed to transfer the commercial rights of a breast cancer therapy to Rigel Pharmaceuticals. The drug had just received regulatory approval, marking a mileston…